By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cost of Injection Jumps from $15 to $1,500
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Cost of Injection Jumps from $15 to $1,500
BusinessHealth Reform

Cost of Injection Jumps from $15 to $1,500

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

The following is from an AP story. See also Merrill Goozner’s comments here.

A drug for high-risk pregnant women has cost about $10 to $20 per injection. Next week, the price shoots up to $1,500 a dose, meaning the total cost during a pregnancy could be as much as $30,000.

That’s because the drug, a form of progesterone given as a weekly shot, has been made cheaply for years, mixed in special pharmacies that custom-compound treatments that are not federally approved ….. But recently, KV Pharmaceutical of suburban St.Louis won government approval to exclusively sell the drug, known as Makena (Mah-KEE’-Nah). ….. The cost is justified to avoid the mental and physical disabilities that can come with very premature births, said KV Pharmaceutical chief executive Gregory J. Divis Jr. The cost of care for a preemie is estimated at $51,000 in the first year alone.To get FDA approval, the company is spending hundreds of millions of dollars in additional research, including an international study involving 1,700 women, Divis said. The FDA last month signed off and gave Makena orphan drug status. That designation ensures Ther-Rx will be the sole source of the drug for seven years.

More Read

New Healthcare Models Stand “Standard of Care” on Its Head
Schumer’s Completely Unhelpful Approach to Curbing Drug Shortages
Hospital Reporting of Surgical-Site Infection Rates
RSNA 2013: Obamacare and Manufacturers – A Siemens Perspective
Collaborative Physician Engagement

Last month, KV sent cease-and-desist letters to compounding pharmacies, telling them they could face FDA enforcement actions if they kept making the drug.

TAGGED:health care businesshealth care reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

woman wearing white long sleeved shirt
Common Mistakes When Trying to Treat Hair Fall at Home
Fitness
March 20, 2026
Sunnyside Dentistry For Children: A Pediatric Dentist’s Pacific Northwest Story
Sunnyside Dentistry For Children: A Pediatric Dentist’s Pacific Northwest Story
Dental health
March 19, 2026
How Expanding Outpatient Nursing Options Is Reshaping Career Trajectories
Career Nursing
March 18, 2026
health care workers working together
How an MBA Healthcare Management Online Program Equips Leaders for Tomorrow
Health
March 18, 2026

You Might also Like

Making The Decision To Outsource And Choosing The Right IRO Partner

October 19, 2015
How Your Hospital Should Be Preparing for VR Healthcare
Hospital AdministrationMedical Innovations

How Your Hospital Should Be Preparing for VR Healthcare

December 7, 2017
internet presence
BusinesseHealth

Top 7 Reasons a Busy Doctor Needs a Powerful Website

January 10, 2015

Choosing a Provider, Ethics, and Playing Darts Blindfolded

July 19, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?